1. Home
  2. PNTG vs MLYS Comparison

PNTG vs MLYS Comparison

Compare PNTG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PNTG
  • MLYS
  • Stock Information
  • Founded
  • PNTG 2019
  • MLYS 2019
  • Country
  • PNTG United States
  • MLYS United States
  • Employees
  • PNTG N/A
  • MLYS N/A
  • Industry
  • PNTG Medical/Nursing Services
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PNTG Health Care
  • MLYS Health Care
  • Exchange
  • PNTG Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • PNTG 873.8M
  • MLYS 890.6M
  • IPO Year
  • PNTG N/A
  • MLYS 2023
  • Fundamental
  • Price
  • PNTG $25.17
  • MLYS $14.89
  • Analyst Decision
  • PNTG Buy
  • MLYS Strong Buy
  • Analyst Count
  • PNTG 6
  • MLYS 4
  • Target Price
  • PNTG $34.17
  • MLYS $27.00
  • AVG Volume (30 Days)
  • PNTG 422.2K
  • MLYS 869.6K
  • Earning Date
  • PNTG 08-06-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • PNTG N/A
  • MLYS N/A
  • EPS Growth
  • PNTG 20.56
  • MLYS N/A
  • EPS
  • PNTG 0.77
  • MLYS N/A
  • Revenue
  • PNTG $798,923,000.00
  • MLYS N/A
  • Revenue This Year
  • PNTG $25.01
  • MLYS N/A
  • Revenue Next Year
  • PNTG $8.18
  • MLYS N/A
  • P/E Ratio
  • PNTG $32.06
  • MLYS N/A
  • Revenue Growth
  • PNTG 30.58
  • MLYS N/A
  • 52 Week Low
  • PNTG $21.18
  • MLYS $8.24
  • 52 Week High
  • PNTG $37.13
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • PNTG 53.03
  • MLYS 55.68
  • Support Level
  • PNTG $24.73
  • MLYS $14.26
  • Resistance Level
  • PNTG $27.16
  • MLYS $15.55
  • Average True Range (ATR)
  • PNTG 1.03
  • MLYS 0.85
  • MACD
  • PNTG 0.17
  • MLYS 0.18
  • Stochastic Oscillator
  • PNTG 62.05
  • MLYS 77.53

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: